June 13, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Exercise declined in patients with obesity after starting a GLP-1
CHICAGO — In patients with obesity, exercise as assessed by wearable-measured activity declined after they initiated GLP-1 receptor agonist therapy, according to findings presented at ENDO 2026. “GLP-1 receptor agonists are now used by millions of adults for weight loss, and we know from prior work that exercise is critical for preserving lean muscle and sustaining long-term weight reduction,”
TL;DRAI
ENDO 2026: wearable-measured activity declined in 753 patients after GLP-1 initiation (steps 5,047→4,487). Steeper decline in men and those with musculoskeletal pain; exercise must be actively prescribed, not assumed from weight loss.
778 words~4 min read
